Press releases

Chordate Medical has signed an agreement with another clinic for the Ozilia treatment for chronic migraine. The client is a specialist clinic in Munich...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
The following resolutions was adopted at the extraordinary general meeting of Chordate Medical Holding AB (publ) held on January 26th, 2024. Reduction...
The analysis firm Kalqyl has today, January 24, 2024, published a new company analysis of Chordate Medical. The analysis is based on the perspective of...
Chordate Medical has now completed the training of clinic staff and assisted in the initiation of treatment for the first three patients at the private...
Chordate Medical Holding AB (publ) hereby announces that the company has entered into an agreement with Vator Securities AB (“Vator Securities”)...
The shareholders in Chordate Medical Holding AB (publ), 556962-6319, are hereby given notice of the extraordinary general meeting to be held on Friday...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
Chordate Medical Holding AB (publ) (“Chordate”) announces today that the first seven patients have been included in the company’s post-Market...
Chordate Medical's CEO Anders Weilandt and CSO Jan Hermansson are currently in Barcelona at the European Headache Congress to present Ozilia to the...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact